Search

Your search keyword '"Castelnovo, Giovanni"' showing total 529 results

Search Constraints

Start Over You searched for: Author "Castelnovo, Giovanni" Remove constraint Author: "Castelnovo, Giovanni"
529 results on '"Castelnovo, Giovanni"'

Search Results

1. Amantadine use in the French prospective NS-Park cohort

7. Clinical and genetic keys to cerebellar ataxia due to FGF14 GAA expansions

8. Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial

10. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study

11. CD138 as a Specific CSF Biomarker of Multiple Sclerosis

12. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study

13. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies

17. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers

18. Incobotulinum toxin A in Parkinson's disease with foot dystonia: A double blind randomized trial

21. Characterization of novel CACNA1A splice variants by RNA‐sequencing in patients with episodic or congenital ataxia

22. Syndecan-1 as specific cerebrospinal fluid biomarker of multiple sclerosis

25. Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study.

26. The radiologically isolated syndrome: revised diagnostic criteria

27. Personalized dietary advices provided by a dietitian increase calcium intake in outpatients with multiple sclerosis—Results from a randomized, controlled, single-blind trial

28. The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus

30. Night-Time Apomorphine Infusion: Who Are the Best Candidates?

31. Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters

32. Night‐Time Apomorphine Infusion: Who Are the Best Candidates?

33. Immune‐mediated diseases involving central and peripheral nervous systems

34. Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome

35. MRI volumetric morphometry in vascular parkinsonism

37. Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

39. Plasma oxysterols: biomarkers for diagnosis and treatment in spastic paraplegia type 5

40. Quantification of Head Tremors in Medical Conditions: A Comparison of Analyses Using a 2D Video Camera and a 3D Wireless Inertial Motion Unit

41. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies

42. Plasma Amyloid Beta Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment: The BALTAZAR Study

43. Immune‐mediated diseases involving central and peripheral nervous systems.

44. Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls

46. High rate of hypomorphic variants as the cause of inherited ataxia and related diseases: study of a cohort of 366 families

47. Evaluation of CSF1R‐related adult onset leukoencephalopathy with axonal spheroids and pigmented glia diagnostic criteria

49. A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study

Catalog

Books, media, physical & digital resources